Health Security Agency (UKHSA) posted on April 24, 2024, shows that malaria diagnosed in England, Wales, and Northern Ireland reached 2,004 reported cases in 2023, a 32% increase from 1,369 in 2022. The rise is linked to the resurgence of malaria in many countries and an increase in overseas travel, says the UKHSA
Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced that its selective cathepsin K inhibitor, MIV-711, has been granted Rare Paediatric Disease Designation (RPDD) as well as Orphan Drug Designation (ODD) for the treatment of Legg-Calvé-Perthes Disease (LCPD).
AstraZeneca’s earnings surprise investors as cancer drugs fuel growth
Merck plans €300m investment at new German research centre
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
Both Destiny and Santhera explained why a tighter clinical focus comes at the expense of one of their potential assets
Sen. Bernie Sanders, I-Vermont, is taking Novo Nordisk to task for allegedly turning its blockbuster GLP-1s Ozempic and Wegovy into “luxury goods.”
STOCKHOLM, SWEDEN / ACCESSWIRE / April 25, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - March 2024 is now available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/
AstraZeneca beats revenue, profit estimates on resilient demand
About 3.6 mln Medicare beneficiaries could be eligible for Wegovy coverage, study shows